Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept for Renal Allograft Tolerance Through Mixed Chimerism
NCT02314403Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2015
- Primary completion
- Mar 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of belatacept in kidney failure and Renal Insufficiency (RI), sponsored by Massachusetts General Hospital. Started Feb 2015; status: completed.
02
Drugs
belatacept
03
Conditions
kidney failureRenal Insufficiency (RI)
Beyond the preview
Go deeper on NCT02314403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314403.